# PeptideScanner evidence objects: Thymosin alpha-1

Every published version of the records placed with Thymosin alpha-1, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json. Selected public evidence only; not medical advice.

- Objects: 48
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00001036-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT00001036

> PeptideScanner retained ClinicalTrials.gov record NCT00001036 at 2026-11-15T22:10:40.222Z. Its registry update date was 2008-07-30, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct00001036-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-07-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00001036-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00001036-thymosin-alpha-1-v1
- Content SHA-256: `b1584e6b0b4638394a3392031c55b75c09d872408b16123157a5308376479a63`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00001036 ([`ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1`](#source-ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00001036 at 2026-11-15T22:10:40.222Z. Its registry update date was 2008-07-30, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1`](#source-ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00001036 at 2026-11-15T22:10:40.222Z. Its registry update date was 2008-07-30, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1`](#source-ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1`](#source-ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1))

### Sources

<a id="source-ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1"></a>
- **ClinicalTrials.gov record NCT00001036 · retained source version 2008-07-30:c6f83c4e50e195abf2a18bae43cf8818e49f859c1b65c232eb44c3267115c994** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00001036) (`ctg-observation-nct00001036-2008-07-30-c6f83c4e50e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00001036." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00001036-thymosin-alpha-1-v1 SHA-256: b1584e6b0b4638394a3392031c55b75c09d872408b16123157a5308376479a63.

---

<a id="clinicaltrials-gov-nct00711620-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT00711620

> PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct00711620-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-06-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00711620-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00711620-thymosin-alpha-1-v1
- Content SHA-256: `d74464e1fd8a8b6cdce3d88ef496906606f0154cdac99779b5e37946148621f9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00711620 ([`ctg-observation-nct00711620-2011-06-14-51885124a914`](#source-ctg-observation-nct00711620-2011-06-14-51885124a914))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00711620-2011-06-14-51885124a914`](#source-ctg-observation-nct00711620-2011-06-14-51885124a914))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00711620-2011-06-14-51885124a914`](#source-ctg-observation-nct00711620-2011-06-14-51885124a914))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00711620-2011-06-14-51885124a914`](#source-ctg-observation-nct00711620-2011-06-14-51885124a914))

### Sources

<a id="source-ctg-observation-nct00711620-2011-06-14-51885124a914"></a>
- **ClinicalTrials.gov record NCT00711620 · retained source version 2011-06-14:51885124a914c8d2fc36c6017bbf5bda8f574f50ec595082552af29a995e5104** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00711620) (`ctg-observation-nct00711620-2011-06-14-51885124a914`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00711620." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00711620-thymosin-alpha-1-v1 SHA-256: d74464e1fd8a8b6cdce3d88ef496906606f0154cdac99779b5e37946148621f9.

---

<a id="clinicaltrials-gov-nct00911443-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT00911443

> PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct00911443-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-07-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00911443-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00911443-thymosin-alpha-1-v1
- Content SHA-256: `66e9e146693895d56a006d85aec6f3fb3ddb6727fb2f18249ea286a11780203d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00911443 ([`ctg-observation-nct00911443-2009-07-09-e5373ac11104`](#source-ctg-observation-nct00911443-2009-07-09-e5373ac11104))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00911443-2009-07-09-e5373ac11104`](#source-ctg-observation-nct00911443-2009-07-09-e5373ac11104))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct00911443-2009-07-09-e5373ac11104`](#source-ctg-observation-nct00911443-2009-07-09-e5373ac11104))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00911443-2009-07-09-e5373ac11104`](#source-ctg-observation-nct00911443-2009-07-09-e5373ac11104))

### Sources

<a id="source-ctg-observation-nct00911443-2009-07-09-e5373ac11104"></a>
- **ClinicalTrials.gov record NCT00911443 · retained source version 2009-07-09:e5373ac1110483b7efc0022ad5c16f6221a6c82367f9fa7857794e7816050842** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00911443) (`ctg-observation-nct00911443-2009-07-09-e5373ac11104`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00911443." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct00911443-thymosin-alpha-1-v1 SHA-256: 66e9e146693895d56a006d85aec6f3fb3ddb6727fb2f18249ea286a11780203d.

---

<a id="clinicaltrials-gov-nct01031966-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT01031966

> PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct01031966-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-03-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01031966-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct01031966-thymosin-alpha-1-v1
- Content SHA-256: `089f6f7d8b0d98f78111f97a482c14aa746621ccd06e3e33b317c5bf753df049`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01031966 ([`ctg-observation-nct01031966-2012-03-29-16ac79aaa2af`](#source-ctg-observation-nct01031966-2012-03-29-16ac79aaa2af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct01031966-2012-03-29-16ac79aaa2af`](#source-ctg-observation-nct01031966-2012-03-29-16ac79aaa2af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01031966 at 2026-11-15T22:10:40.222Z. Its registry update date was 2012-03-29, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct01031966-2012-03-29-16ac79aaa2af`](#source-ctg-observation-nct01031966-2012-03-29-16ac79aaa2af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01031966-2012-03-29-16ac79aaa2af`](#source-ctg-observation-nct01031966-2012-03-29-16ac79aaa2af))

### Sources

<a id="source-ctg-observation-nct01031966-2012-03-29-16ac79aaa2af"></a>
- **ClinicalTrials.gov record NCT01031966 · retained source version 2012-03-29:16ac79aaa2afafdfd404ed1bfd8d4219d2e24fc6b26d6678ee0b2170428bbaff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01031966) (`ctg-observation-nct01031966-2012-03-29-16ac79aaa2af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01031966." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct01031966-thymosin-alpha-1-v1 SHA-256: 089f6f7d8b0d98f78111f97a482c14aa746621ccd06e3e33b317c5bf753df049.

---

<a id="clinicaltrials-gov-nct01178996-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT01178996

> PeptideScanner retained ClinicalTrials.gov record NCT01178996 at 2026-11-15T22:10:40.222Z. Its registry update date was 2010-08-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct01178996-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-08-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01178996-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct01178996-thymosin-alpha-1-v1
- Content SHA-256: `2c002511edfb714083a805dd18e6615af27e02d1fe0d77f8e1e7e6d96d8233f9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01178996 ([`ctg-observation-nct01178996-2010-08-10-684dcd5dc87f`](#source-ctg-observation-nct01178996-2010-08-10-684dcd5dc87f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01178996 at 2026-11-15T22:10:40.222Z. Its registry update date was 2010-08-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct01178996-2010-08-10-684dcd5dc87f`](#source-ctg-observation-nct01178996-2010-08-10-684dcd5dc87f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01178996 at 2026-11-15T22:10:40.222Z. Its registry update date was 2010-08-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct01178996-2010-08-10-684dcd5dc87f`](#source-ctg-observation-nct01178996-2010-08-10-684dcd5dc87f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01178996-2010-08-10-684dcd5dc87f`](#source-ctg-observation-nct01178996-2010-08-10-684dcd5dc87f))

### Sources

<a id="source-ctg-observation-nct01178996-2010-08-10-684dcd5dc87f"></a>
- **ClinicalTrials.gov record NCT01178996 · retained source version 2010-08-10:684dcd5dc87f473bb9ebcf91674b0fe616f9a2006aac8945e1dc2e9173345960** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01178996) (`ctg-observation-nct01178996-2010-08-10-684dcd5dc87f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01178996." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct01178996-thymosin-alpha-1-v1 SHA-256: 2c002511edfb714083a805dd18e6615af27e02d1fe0d77f8e1e7e6d96d8233f9.

---

<a id="clinicaltrials-gov-nct02473406-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT02473406

> PeptideScanner retained ClinicalTrials.gov record NCT02473406 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct02473406-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-04-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02473406-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02473406-thymosin-alpha-1-v1
- Content SHA-256: `9182c1012c5448e844f9594c5f510cfbf3c62f8c11b28dec4547350b30836ace`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02473406 ([`ctg-observation-nct02473406-2021-04-05-0155375039ca`](#source-ctg-observation-nct02473406-2021-04-05-0155375039ca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02473406 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02473406-2021-04-05-0155375039ca`](#source-ctg-observation-nct02473406-2021-04-05-0155375039ca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02473406 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02473406-2021-04-05-0155375039ca`](#source-ctg-observation-nct02473406-2021-04-05-0155375039ca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02473406-2021-04-05-0155375039ca`](#source-ctg-observation-nct02473406-2021-04-05-0155375039ca))

### Sources

<a id="source-ctg-observation-nct02473406-2021-04-05-0155375039ca"></a>
- **ClinicalTrials.gov record NCT02473406 · retained source version 2021-04-05:0155375039ca802db3b3739ea7b8cbdff1afcbe1c5dcc4e874aaa7b2da6907a8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02473406) (`ctg-observation-nct02473406-2021-04-05-0155375039ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02473406." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02473406-thymosin-alpha-1-v1 SHA-256: 9182c1012c5448e844f9594c5f510cfbf3c62f8c11b28dec4547350b30836ace.

---

<a id="clinicaltrials-gov-nct02646189-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT02646189

> PeptideScanner retained ClinicalTrials.gov record NCT02646189 at 2026-11-15T22:10:40.222Z. Its registry update date was 2016-01-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct02646189-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-01-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02646189-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02646189-thymosin-alpha-1-v1
- Content SHA-256: `f31dc53f9301a4f40dd43dd676418dfa13bfaf37eb5ac5783cca347614be1e2a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02646189 ([`ctg-observation-nct02646189-2016-01-05-5d1291c4c493`](#source-ctg-observation-nct02646189-2016-01-05-5d1291c4c493))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02646189 at 2026-11-15T22:10:40.222Z. Its registry update date was 2016-01-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02646189-2016-01-05-5d1291c4c493`](#source-ctg-observation-nct02646189-2016-01-05-5d1291c4c493))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02646189 at 2026-11-15T22:10:40.222Z. Its registry update date was 2016-01-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02646189-2016-01-05-5d1291c4c493`](#source-ctg-observation-nct02646189-2016-01-05-5d1291c4c493))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02646189-2016-01-05-5d1291c4c493`](#source-ctg-observation-nct02646189-2016-01-05-5d1291c4c493))

### Sources

<a id="source-ctg-observation-nct02646189-2016-01-05-5d1291c4c493"></a>
- **ClinicalTrials.gov record NCT02646189 · retained source version 2016-01-05:5d1291c4c49337624b93a4badce6b80d57a2560e293cb566d4ca5a946ac7a5c2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02646189) (`ctg-observation-nct02646189-2016-01-05-5d1291c4c493`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02646189." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02646189-thymosin-alpha-1-v1 SHA-256: f31dc53f9301a4f40dd43dd676418dfa13bfaf37eb5ac5783cca347614be1e2a.

---

<a id="clinicaltrials-gov-nct02867267-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT02867267

> PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct02867267-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-04-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02867267-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02867267-thymosin-alpha-1-v1
- Content SHA-256: `d0e602446e2ec1d874423af4864423d8a77dbe65dba327c90c95679261def169`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02867267 ([`ctg-observation-nct02867267-2023-04-10-b86f32ef72aa`](#source-ctg-observation-nct02867267-2023-04-10-b86f32ef72aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02867267-2023-04-10-b86f32ef72aa`](#source-ctg-observation-nct02867267-2023-04-10-b86f32ef72aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02867267-2023-04-10-b86f32ef72aa`](#source-ctg-observation-nct02867267-2023-04-10-b86f32ef72aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02867267-2023-04-10-b86f32ef72aa`](#source-ctg-observation-nct02867267-2023-04-10-b86f32ef72aa))

### Sources

<a id="source-ctg-observation-nct02867267-2023-04-10-b86f32ef72aa"></a>
- **ClinicalTrials.gov record NCT02867267 · retained source version 2023-04-10:b86f32ef72aa30e7e8e1cd93079f8a0ac2826e9d6830896e9929bf56c7c10158** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02867267) (`ctg-observation-nct02867267-2023-04-10-b86f32ef72aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02867267." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02867267-thymosin-alpha-1-v1 SHA-256: d0e602446e2ec1d874423af4864423d8a77dbe65dba327c90c95679261def169.

---

<a id="clinicaltrials-gov-nct02883595-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT02883595

> PeptideScanner retained ClinicalTrials.gov record NCT02883595 at 2026-11-15T22:10:40.222Z. Its registry update date was 2019-04-04, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct02883595-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-04-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02883595-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02883595-thymosin-alpha-1-v1
- Content SHA-256: `508ef05d09f353734dd51d550e32faed7775a468093bfb690c492eb0b73d8e96`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02883595 ([`ctg-observation-nct02883595-2019-04-04-c729fc9aadc8`](#source-ctg-observation-nct02883595-2019-04-04-c729fc9aadc8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02883595 at 2026-11-15T22:10:40.222Z. Its registry update date was 2019-04-04, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02883595-2019-04-04-c729fc9aadc8`](#source-ctg-observation-nct02883595-2019-04-04-c729fc9aadc8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02883595 at 2026-11-15T22:10:40.222Z. Its registry update date was 2019-04-04, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct02883595-2019-04-04-c729fc9aadc8`](#source-ctg-observation-nct02883595-2019-04-04-c729fc9aadc8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02883595-2019-04-04-c729fc9aadc8`](#source-ctg-observation-nct02883595-2019-04-04-c729fc9aadc8))

### Sources

<a id="source-ctg-observation-nct02883595-2019-04-04-c729fc9aadc8"></a>
- **ClinicalTrials.gov record NCT02883595 · retained source version 2019-04-04:c729fc9aadc8a18ca1f3725165c51cffee129f1fce75c74d61e40e449645f611** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02883595) (`ctg-observation-nct02883595-2019-04-04-c729fc9aadc8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02883595." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct02883595-thymosin-alpha-1-v1 SHA-256: 508ef05d09f353734dd51d550e32faed7775a468093bfb690c492eb0b73d8e96.

---

<a id="clinicaltrials-gov-nct03659578-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT03659578

> PeptideScanner retained ClinicalTrials.gov record NCT03659578 at 2026-11-15T22:10:40.222Z. Its registry update date was 2022-01-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct03659578-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03659578-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct03659578-thymosin-alpha-1-v1
- Content SHA-256: `dc5b8896f8af88d38d1151d1ac62930554cb29510260537679e3427b6b78b991`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03659578 ([`ctg-observation-nct03659578-2022-01-03-4144f9702a2e`](#source-ctg-observation-nct03659578-2022-01-03-4144f9702a2e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03659578 at 2026-11-15T22:10:40.222Z. Its registry update date was 2022-01-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct03659578-2022-01-03-4144f9702a2e`](#source-ctg-observation-nct03659578-2022-01-03-4144f9702a2e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03659578 at 2026-11-15T22:10:40.222Z. Its registry update date was 2022-01-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct03659578-2022-01-03-4144f9702a2e`](#source-ctg-observation-nct03659578-2022-01-03-4144f9702a2e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03659578-2022-01-03-4144f9702a2e`](#source-ctg-observation-nct03659578-2022-01-03-4144f9702a2e))

### Sources

<a id="source-ctg-observation-nct03659578-2022-01-03-4144f9702a2e"></a>
- **ClinicalTrials.gov record NCT03659578 · retained source version 2022-01-03:4144f9702a2ed3cfe271e66f674bade8ddd0b2606deb4cf8f8380233b9e4ebca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03659578) (`ctg-observation-nct03659578-2022-01-03-4144f9702a2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03659578." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct03659578-thymosin-alpha-1-v1 SHA-256: dc5b8896f8af88d38d1151d1ac62930554cb29510260537679e3427b6b78b991.

---

<a id="clinicaltrials-gov-nct04428008-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT04428008

> PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct04428008-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04428008-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct04428008-thymosin-alpha-1-v1
- Content SHA-256: `95208c27599d5931e45edd8e5cb831adc77686ea4a15f5d8a81137a565a4dac5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04428008 ([`ctg-observation-nct04428008-2026-04-21-793d18956433`](#source-ctg-observation-nct04428008-2026-04-21-793d18956433))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct04428008-2026-04-21-793d18956433`](#source-ctg-observation-nct04428008-2026-04-21-793d18956433))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct04428008-2026-04-21-793d18956433`](#source-ctg-observation-nct04428008-2026-04-21-793d18956433))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04428008-2026-04-21-793d18956433`](#source-ctg-observation-nct04428008-2026-04-21-793d18956433))

### Sources

<a id="source-ctg-observation-nct04428008-2026-04-21-793d18956433"></a>
- **ClinicalTrials.gov record NCT04428008 · retained source version 2026-04-21:793d18956433a6b95a3ff2ad903e14b4523f84974b223bf8b327d05389e16d65** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04428008) (`ctg-observation-nct04428008-2026-04-21-793d18956433`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04428008." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct04428008-thymosin-alpha-1-v1 SHA-256: 95208c27599d5931e45edd8e5cb831adc77686ea4a15f5d8a81137a565a4dac5.

---

<a id="clinicaltrials-gov-nct05086614-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT05086614

> PeptideScanner retained ClinicalTrials.gov record NCT05086614 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-10-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct05086614-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05086614-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct05086614-thymosin-alpha-1-v1
- Content SHA-256: `d3e955c5dc3415bf9fca2e228253871ba5e685fffdd718cb60c0e8e5ef68a730`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05086614 ([`ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e`](#source-ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05086614 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-10-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e`](#source-ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05086614 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-10-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e`](#source-ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e`](#source-ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e))

### Sources

<a id="source-ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e"></a>
- **ClinicalTrials.gov record NCT05086614 · retained source version 2021-10-21:1fa7f4870c8e18dd0588d15d158216de403e012192fde3e5a6673962c69a6044** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05086614) (`ctg-observation-nct05086614-2021-10-21-1fa7f4870c8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05086614." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct05086614-thymosin-alpha-1-v1 SHA-256: d3e955c5dc3415bf9fca2e228253871ba5e685fffdd718cb60c0e8e5ef68a730.

---

<a id="clinicaltrials-gov-nct06024356-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT06024356

> PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct06024356-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06024356-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06024356-thymosin-alpha-1-v1
- Content SHA-256: `d9dae2610f260145af363e77f60aa938e7017bd2f3de012b0a27823aad19b362`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06024356 ([`ctg-observation-nct06024356-2026-06-18-6263381379e8`](#source-ctg-observation-nct06024356-2026-06-18-6263381379e8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06024356-2026-06-18-6263381379e8`](#source-ctg-observation-nct06024356-2026-06-18-6263381379e8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06024356-2026-06-18-6263381379e8`](#source-ctg-observation-nct06024356-2026-06-18-6263381379e8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06024356-2026-06-18-6263381379e8`](#source-ctg-observation-nct06024356-2026-06-18-6263381379e8))

### Sources

<a id="source-ctg-observation-nct06024356-2026-06-18-6263381379e8"></a>
- **ClinicalTrials.gov record NCT06024356 · retained source version 2026-06-18:6263381379e88846f274192a97475f4d194b78009cc6154ed086fbcd55030de2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06024356) (`ctg-observation-nct06024356-2026-06-18-6263381379e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06024356." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06024356-thymosin-alpha-1-v1 SHA-256: d9dae2610f260145af363e77f60aa938e7017bd2f3de012b0a27823aad19b362.

---

<a id="clinicaltrials-gov-nct06139419-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT06139419

> PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct06139419-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06139419-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06139419-thymosin-alpha-1-v1
- Content SHA-256: `1ac334f5a0ecfb48be3ac24b79711ec0038573f844b60789cf9e56ac3a41ea6d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06139419 ([`ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf`](#source-ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf`](#source-ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf`](#source-ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf`](#source-ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf))

### Sources

<a id="source-ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf"></a>
- **ClinicalTrials.gov record NCT06139419 · retained source version 2026-08-03:0a01c8ce97bfd8dc6124a03c4b9e44d0a41ab9052875084ff79ff1f7e03338af** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06139419) (`ctg-observation-nct06139419-2026-08-03-0a01c8ce97bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06139419." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06139419-thymosin-alpha-1-v1 SHA-256: 1ac334f5a0ecfb48be3ac24b79711ec0038573f844b60789cf9e56ac3a41ea6d.

---

<a id="clinicaltrials-gov-nct06461910-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT06461910

> PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct06461910-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06461910-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06461910-thymosin-alpha-1-v1
- Content SHA-256: `91a60b21b1fb748d492acfde05a9886632d9004cbe4ca813f962f6973f517e65`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06461910 ([`ctg-observation-nct06461910-2026-03-03-059bac03445d`](#source-ctg-observation-nct06461910-2026-03-03-059bac03445d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06461910-2026-03-03-059bac03445d`](#source-ctg-observation-nct06461910-2026-03-03-059bac03445d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct06461910-2026-03-03-059bac03445d`](#source-ctg-observation-nct06461910-2026-03-03-059bac03445d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06461910-2026-03-03-059bac03445d`](#source-ctg-observation-nct06461910-2026-03-03-059bac03445d))

### Sources

<a id="source-ctg-observation-nct06461910-2026-03-03-059bac03445d"></a>
- **ClinicalTrials.gov record NCT06461910 · retained source version 2026-03-03:059bac03445db3615d2c3ef7db745e78c8f4faac786186b3540ea3c693b5f87a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06461910) (`ctg-observation-nct06461910-2026-03-03-059bac03445d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06461910." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct06461910-thymosin-alpha-1-v1 SHA-256: 91a60b21b1fb748d492acfde05a9886632d9004cbe4ca813f962f6973f517e65.

---

<a id="clinicaltrials-gov-nct07780721-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT07780721

> PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct07780721-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07780721-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07780721-thymosin-alpha-1-v1
- Content SHA-256: `e34ca6a34433f828fe4f26fbdb9f83b642aa0a1ecc9d193a2743bc735825cbb4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07780721 ([`ctg-observation-nct07780721-2026-08-21-eac5dfa235e1`](#source-ctg-observation-nct07780721-2026-08-21-eac5dfa235e1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07780721-2026-08-21-eac5dfa235e1`](#source-ctg-observation-nct07780721-2026-08-21-eac5dfa235e1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07780721-2026-08-21-eac5dfa235e1`](#source-ctg-observation-nct07780721-2026-08-21-eac5dfa235e1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07780721-2026-08-21-eac5dfa235e1`](#source-ctg-observation-nct07780721-2026-08-21-eac5dfa235e1))

### Sources

<a id="source-ctg-observation-nct07780721-2026-08-21-eac5dfa235e1"></a>
- **ClinicalTrials.gov record NCT07780721 · retained source version 2026-08-21:eac5dfa235e145cc284335cbc73f74170f0690955227106a5bd112f480dd7d24** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07780721) (`ctg-observation-nct07780721-2026-08-21-eac5dfa235e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07780721." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07780721-thymosin-alpha-1-v1 SHA-256: e34ca6a34433f828fe4f26fbdb9f83b642aa0a1ecc9d193a2743bc735825cbb4.

---

<a id="clinicaltrials-gov-nct07884201-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT07884201

> PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct07884201-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07884201-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07884201-thymosin-alpha-1-v1
- Content SHA-256: `747e1f6c298cd610c13f332d5581e66154719729353330a7f4ba7babd69d5f84`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07884201 ([`ctg-observation-nct07884201-2026-10-20-ed94c2343a31`](#source-ctg-observation-nct07884201-2026-10-20-ed94c2343a31))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07884201-2026-10-20-ed94c2343a31`](#source-ctg-observation-nct07884201-2026-10-20-ed94c2343a31))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07884201-2026-10-20-ed94c2343a31`](#source-ctg-observation-nct07884201-2026-10-20-ed94c2343a31))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07884201-2026-10-20-ed94c2343a31`](#source-ctg-observation-nct07884201-2026-10-20-ed94c2343a31))

### Sources

<a id="source-ctg-observation-nct07884201-2026-10-20-ed94c2343a31"></a>
- **ClinicalTrials.gov record NCT07884201 · retained source version 2026-10-20:ed94c2343a31cffc8f27134bb82a7294ed0dd408721b8556aee388a2da690c87** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07884201) (`ctg-observation-nct07884201-2026-10-20-ed94c2343a31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07884201." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07884201-thymosin-alpha-1-v1 SHA-256: 747e1f6c298cd610c13f332d5581e66154719729353330a7f4ba7babd69d5f84.

---

<a id="clinicaltrials-gov-nct07922954-thymosin-alpha-1-v1"></a>

## ClinicalTrials.gov record NCT07922954

> PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

- Evidence object: `story:clinicaltrials-gov-nct07922954-thymosin-alpha-1:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07922954-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07922954-thymosin-alpha-1-v1
- Content SHA-256: `18c6a257d4ec7a2410e3cef1f2e10788dfa56779cadfa1ed332d11696797ae34`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07922954 ([`ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0`](#source-ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0`](#source-ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1. ([`ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0`](#source-ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0`](#source-ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0))

### Sources

<a id="source-ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0"></a>
- **ClinicalTrials.gov record NCT07922954 · retained source version 2026-11-06:ed3cdbf8f3d019a0155cbd96898584ab2d6e82ada6a3a9abeb8f82e77b6f5a0d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07922954) (`ctg-observation-nct07922954-2026-11-06-ed3cdbf8f3d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07922954." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#clinicaltrials-gov-nct07922954-thymosin-alpha-1-v1 SHA-256: 18c6a257d4ec7a2410e3cef1f2e10788dfa56779cadfa1ed332d11696797ae34.

---

<a id="pubmed-pmid-11381492-thymosin-alpha-1-v1"></a>

## Thymosin alpha-1.

> PubMed lists PMID 11381492 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, Review, with publication-date metadata of 2001-05-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11381492-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11381492-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-11381492-thymosin-alpha-1-v1
- Content SHA-256: `533afdb9fe9d863176233dab8a2a726953a8228283f8df87b4882aabc7655a94`

### Claims and source pins

#### Headline

Thymosin alpha-1. ([`pubmed-observation-pmid-11381492-2019-02-22-73b82868b925`](#source-pubmed-observation-pmid-11381492-2019-02-22-73b82868b925))

#### Summary

PubMed lists PMID 11381492 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, Review, with publication-date metadata of 2001-05-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11381492-2019-02-22-73b82868b925`](#source-pubmed-observation-pmid-11381492-2019-02-22-73b82868b925))

#### Paragraph 1

PubMed lists PMID 11381492 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, Review, with publication-date metadata of 2001-05-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11381492-2019-02-22-73b82868b925`](#source-pubmed-observation-pmid-11381492-2019-02-22-73b82868b925))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11381492-2019-02-22-73b82868b925`](#source-pubmed-observation-pmid-11381492-2019-02-22-73b82868b925))

### Sources

<a id="source-pubmed-observation-pmid-11381492-2019-02-22-73b82868b925"></a>
- **Thymosin alpha-1. · retained source version 1:2019-02-22:current:73b82868b9259b13a4df4593554042a6a29d09306e94b76b54fa72f5f2452f21** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11381492/) (`pubmed-observation-pmid-11381492-2019-02-22-73b82868b925`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha-1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-11381492-thymosin-alpha-1-v1 SHA-256: 533afdb9fe9d863176233dab8a2a726953a8228283f8df87b4882aabc7655a94.

---

<a id="pubmed-pmid-12860169-thymosin-alpha-1-v1"></a>

## Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.

> PubMed lists PMID 12860169 in International immunopharmacology as Journal Article, Review, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12860169-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12860169-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-12860169-thymosin-alpha-1-v1
- Content SHA-256: `9ac6e6a1d22f88eef289200952279e8294fc16cf823e80de0b5086903e1c3ec5`

### Claims and source pins

#### Headline

Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. ([`pubmed-observation-pmid-12860169-2018-11-30-0844747aad75`](#source-pubmed-observation-pmid-12860169-2018-11-30-0844747aad75))

#### Summary

PubMed lists PMID 12860169 in International immunopharmacology as Journal Article, Review, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12860169-2018-11-30-0844747aad75`](#source-pubmed-observation-pmid-12860169-2018-11-30-0844747aad75))

#### Paragraph 1

PubMed lists PMID 12860169 in International immunopharmacology as Journal Article, Review, with publication-date metadata of 2003-08 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12860169-2018-11-30-0844747aad75`](#source-pubmed-observation-pmid-12860169-2018-11-30-0844747aad75))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12860169-2018-11-30-0844747aad75`](#source-pubmed-observation-pmid-12860169-2018-11-30-0844747aad75))

### Sources

<a id="source-pubmed-observation-pmid-12860169-2018-11-30-0844747aad75"></a>
- **Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. · retained source version 1:2018-11-30:current:0844747aad755d345f761e83816fa916d83c3f3a0eed38dd581442662c36ef90** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12860169/) (`pubmed-observation-pmid-12860169-2018-11-30-0844747aad75`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-12860169-thymosin-alpha-1-v1 SHA-256: 9ac6e6a1d22f88eef289200952279e8294fc16cf823e80de0b5086903e1c3ec5.

---

<a id="pubmed-pmid-15482167-thymosin-alpha-1-v1"></a>

## Thymalfasin for the treatment of chronic hepatitis B.

> PubMed lists PMID 15482167 in Expert review of anti-infective therapy as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15482167-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15482167-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15482167-thymosin-alpha-1-v1
- Content SHA-256: `4353927f2ca3a199c982b5478abca89692adb56e0045f02620b66b567174f7f5`

### Claims and source pins

#### Headline

Thymalfasin for the treatment of chronic hepatitis B. ([`pubmed-observation-pmid-15482167-2019-11-09-721edf86da03`](#source-pubmed-observation-pmid-15482167-2019-11-09-721edf86da03))

#### Summary

PubMed lists PMID 15482167 in Expert review of anti-infective therapy as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15482167-2019-11-09-721edf86da03`](#source-pubmed-observation-pmid-15482167-2019-11-09-721edf86da03))

#### Paragraph 1

PubMed lists PMID 15482167 in Expert review of anti-infective therapy as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15482167-2019-11-09-721edf86da03`](#source-pubmed-observation-pmid-15482167-2019-11-09-721edf86da03))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15482167-2019-11-09-721edf86da03`](#source-pubmed-observation-pmid-15482167-2019-11-09-721edf86da03))

### Sources

<a id="source-pubmed-observation-pmid-15482167-2019-11-09-721edf86da03"></a>
- **Thymalfasin for the treatment of chronic hepatitis B. · retained source version 1:2019-11-09:current:721edf86da035d59960222b1ac5bb422d5fa3fbfe395f219fa602500019d0061** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15482167/) (`pubmed-observation-pmid-15482167-2019-11-09-721edf86da03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymalfasin for the treatment of chronic hepatitis B." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15482167-thymosin-alpha-1-v1 SHA-256: 4353927f2ca3a199c982b5478abca89692adb56e0045f02620b66b567174f7f5.

---

<a id="pubmed-pmid-15546255-thymosin-alpha-1-v1"></a>

## Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.

> PubMed lists PMID 15546255 in Journal of gastroenterology and hepatology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15546255-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15546255-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15546255-thymosin-alpha-1-v1
- Content SHA-256: `074b46d9d0086029d53b63a629466b392413050c6b4b38c37ede2b958b249cbd`

### Claims and source pins

#### Headline

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. ([`pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d`](#source-pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d))

#### Summary

PubMed lists PMID 15546255 in Journal of gastroenterology and hepatology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d`](#source-pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d))

#### Paragraph 1

PubMed lists PMID 15546255 in Journal of gastroenterology and hepatology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d`](#source-pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d`](#source-pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d))

### Sources

<a id="source-pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d"></a>
- **Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. · retained source version 1:2026-01-28:current:ee7e29fa834d3cdfa9f4ee3dd5e2854f538d3823cfb5cf018066be4145009276** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15546255/) (`pubmed-observation-pmid-15546255-2026-01-28-ee7e29fa834d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15546255-thymosin-alpha-1-v1 SHA-256: 074b46d9d0086029d53b63a629466b392413050c6b4b38c37ede2b958b249cbd.

---

<a id="pubmed-pmid-15641208-thymosin-alpha-1-v1"></a>

## Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.

> PubMed lists PMID 15641208 in Journal of gastroenterology and hepatology as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15641208-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15641208-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15641208-thymosin-alpha-1-v1
- Content SHA-256: `5214f4aacba0d149428f4c570f0c6d8b58d586bff4e8bbb63ecbe1c1293194f4`

### Claims and source pins

#### Headline

Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. ([`pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b`](#source-pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b))

#### Summary

PubMed lists PMID 15641208 in Journal of gastroenterology and hepatology as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b`](#source-pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b))

#### Paragraph 1

PubMed lists PMID 15641208 in Journal of gastroenterology and hepatology as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b`](#source-pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b`](#source-pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b))

### Sources

<a id="source-pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b"></a>
- **Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. · retained source version 1:2018-12-01:current:0f714efb558b2c38a29205517b8a9a0fc5bae1ac7fb6817d38101bd2f5d1e307** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15641208/) (`pubmed-observation-pmid-15641208-2018-12-01-0f714efb558b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15641208-thymosin-alpha-1-v1 SHA-256: 5214f4aacba0d149428f4c570f0c6d8b58d586bff4e8bbb63ecbe1c1293194f4.

---

<a id="pubmed-pmid-15641209-thymosin-alpha-1-v1"></a>

## Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.

> PubMed lists PMID 15641209 in Journal of gastroenterology and hepatology as Clinical Trial, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15641209-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15641209-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15641209-thymosin-alpha-1-v1
- Content SHA-256: `e87b59cab7e7275a5fd01d1ba5d2450de0dc857e7b839afe941197272a044db5`

### Claims and source pins

#### Headline

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. ([`pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4`](#source-pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4))

#### Summary

PubMed lists PMID 15641209 in Journal of gastroenterology and hepatology as Clinical Trial, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4`](#source-pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4))

#### Paragraph 1

PubMed lists PMID 15641209 in Journal of gastroenterology and hepatology as Clinical Trial, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4`](#source-pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4`](#source-pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4))

### Sources

<a id="source-pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4"></a>
- **Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. · retained source version 1:2018-12-01:current:b9b14dc42eb441555b20b11c2ebce965e8fd6edfbf4488822c2604cb7313177b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15641209/) (`pubmed-observation-pmid-15641209-2018-12-01-b9b14dc42eb4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-15641209-thymosin-alpha-1-v1 SHA-256: e87b59cab7e7275a5fd01d1ba5d2450de0dc857e7b839afe941197272a044db5.

---

<a id="pubmed-pmid-16307501-thymosin-alpha-1-v1"></a>

## Thymalfasin for the treatment of chronic hepatitis C infection.

> PubMed lists PMID 16307501 in Expert review of anti-infective therapy as Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16307501-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16307501-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-16307501-thymosin-alpha-1-v1
- Content SHA-256: `7775df9959c74352ec2d4611e824ba1a16fe247f2ef7220b94634b34425e1bcb`

### Claims and source pins

#### Headline

Thymalfasin for the treatment of chronic hepatitis C infection. ([`pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35`](#source-pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35))

#### Summary

PubMed lists PMID 16307501 in Expert review of anti-infective therapy as Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35`](#source-pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35))

#### Paragraph 1

PubMed lists PMID 16307501 in Expert review of anti-infective therapy as Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35`](#source-pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35`](#source-pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35))

### Sources

<a id="source-pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35"></a>
- **Thymalfasin for the treatment of chronic hepatitis C infection. · retained source version 1:2018-12-03:current:bccf74193a359ee75f2303ec02088bdb9a97e40beee7000e5602752c5469333d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16307501/) (`pubmed-observation-pmid-16307501-2018-12-03-bccf74193a35`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymalfasin for the treatment of chronic hepatitis C infection." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-16307501-thymosin-alpha-1-v1 SHA-256: 7775df9959c74352ec2d4611e824ba1a16fe247f2ef7220b94634b34425e1bcb.

---

<a id="pubmed-pmid-17600281-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries.

> PubMed lists PMID 17600281 in Annals of the New York Academy of Sciences as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-28 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17600281-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17600281-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-17600281-thymosin-alpha-1-v1
- Content SHA-256: `b5d5cd81b0f5b29a343dca8ebf649d58c95ff02022028b31bbb03f9ec0c91afd`

### Claims and source pins

#### Headline

Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. ([`pubmed-observation-pmid-17600281-2018-12-01-16def7529435`](#source-pubmed-observation-pmid-17600281-2018-12-01-16def7529435))

#### Summary

PubMed lists PMID 17600281 in Annals of the New York Academy of Sciences as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-28 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17600281-2018-12-01-16def7529435`](#source-pubmed-observation-pmid-17600281-2018-12-01-16def7529435))

#### Paragraph 1

PubMed lists PMID 17600281 in Annals of the New York Academy of Sciences as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2007-06-28 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17600281-2018-12-01-16def7529435`](#source-pubmed-observation-pmid-17600281-2018-12-01-16def7529435))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17600281-2018-12-01-16def7529435`](#source-pubmed-observation-pmid-17600281-2018-12-01-16def7529435))

### Sources

<a id="source-pubmed-observation-pmid-17600281-2018-12-01-16def7529435"></a>
- **Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. · retained source version 1:2018-12-01:current:16def7529435b9d2cda3da4fbb0700aa0a3dbb6697980dad7ed5f785e58f1098** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17600281/) (`pubmed-observation-pmid-17600281-2018-12-01-16def7529435`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-17600281-thymosin-alpha-1-v1 SHA-256: b5d5cd81b0f5b29a343dca8ebf649d58c95ff02022028b31bbb03f9ec0c91afd.

---

<a id="pubmed-pmid-18410608-thymosin-alpha-1-v1"></a>

## Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study.

> PubMed lists PMID 18410608 in Journal of gastroenterology and hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18410608-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18410608-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-18410608-thymosin-alpha-1-v1
- Content SHA-256: `fc4058edf5bc95b30e5c9e0cdc8e2a96c96b01703163c4afaeb507521dc616f9`

### Claims and source pins

#### Headline

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. ([`pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa`](#source-pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa))

#### Summary

PubMed lists PMID 18410608 in Journal of gastroenterology and hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa`](#source-pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa))

#### Paragraph 1

PubMed lists PMID 18410608 in Journal of gastroenterology and hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa`](#source-pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa`](#source-pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa))

### Sources

<a id="source-pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa"></a>
- **Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. · retained source version 1:2018-12-01:current:e36da2b8e3fa4c36ee6530e7f758f690da3ade5c4468c5d684653014d3d3101a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18410608/) (`pubmed-observation-pmid-18410608-2018-12-01-e36da2b8e3fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-18410608-thymosin-alpha-1-v1 SHA-256: fc4058edf5bc95b30e5c9e0cdc8e2a96c96b01703163c4afaeb507521dc616f9.

---

<a id="pubmed-pmid-19033321-thymosin-alpha-1-v1"></a>

## A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.

> PubMed lists PMID 19033321 in Journal of intensive care medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-11-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19033321-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19033321-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19033321-thymosin-alpha-1-v1
- Content SHA-256: `5a9d0b077b3d07d4d7ece6d7e9731713b934683ae37788eeedd05ee388655c96`

### Claims and source pins

#### Headline

A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1. ([`pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1`](#source-pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1))

#### Summary

PubMed lists PMID 19033321 in Journal of intensive care medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-11-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1`](#source-pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1))

#### Paragraph 1

PubMed lists PMID 19033321 in Journal of intensive care medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-11-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1`](#source-pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1`](#source-pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1))

### Sources

<a id="source-pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1"></a>
- **A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1. · retained source version 1:2018-12-01:current:dd9c0bfa8ed11d16fd5d8389973401c7bd2a046c069b364cf108d964bfbcabfb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19033321/) (`pubmed-observation-pmid-19033321-2018-12-01-dd9c0bfa8ed1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19033321-thymosin-alpha-1-v1 SHA-256: 5a9d0b077b3d07d4d7ece6d7e9731713b934683ae37788eeedd05ee388655c96.

---

<a id="pubmed-pmid-19392576-thymosin-alpha-1-v1"></a>

## From lab to bedside: emerging clinical applications of thymosin alpha 1.

> PubMed lists PMID 19392576 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19392576-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19392576-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19392576-thymosin-alpha-1-v1
- Content SHA-256: `1e2b2963e4a6dbbe18af6567b83a50d3cfb3251a9d8a35a5a9b6e32824e475ae`

### Claims and source pins

#### Headline

From lab to bedside: emerging clinical applications of thymosin alpha 1. ([`pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc`](#source-pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc))

#### Summary

PubMed lists PMID 19392576 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc`](#source-pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc))

#### Paragraph 1

PubMed lists PMID 19392576 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc`](#source-pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc`](#source-pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc))

### Sources

<a id="source-pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc"></a>
- **From lab to bedside: emerging clinical applications of thymosin alpha 1. · retained source version 1:2022-03-16:current:bffda92a1abc3f88971609b152f0abbfa89350ba8b2f3b400243793c62b19034** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19392576/) (`pubmed-observation-pmid-19392576-2022-03-16-bffda92a1abc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "From lab to bedside: emerging clinical applications of thymosin alpha 1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19392576-thymosin-alpha-1-v1 SHA-256: 1e2b2963e4a6dbbe18af6567b83a50d3cfb3251a9d8a35a5a9b6e32824e475ae.

---

<a id="pubmed-pmid-19467157-thymosin-alpha-1-v1"></a>

## Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis.

> PubMed lists PMID 19467157 in Virology journal as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19467157-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19467157-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19467157-thymosin-alpha-1-v1
- Content SHA-256: `29d72004eab4ecc560429f230ea308e72f5f1c2e9f229a645cc6e88f54703511`

### Claims and source pins

#### Headline

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. ([`pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d`](#source-pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d))

#### Summary

PubMed lists PMID 19467157 in Virology journal as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d`](#source-pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d))

#### Paragraph 1

PubMed lists PMID 19467157 in Virology journal as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2009-05-25 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d`](#source-pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d`](#source-pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d))

### Sources

<a id="source-pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d"></a>
- **Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. · retained source version 1:2024-05-16:current:f0c75ce95f3d3026dfd1a0a546146741a992dfaf5d091833a011b7710e5046a8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19467157/) (`pubmed-observation-pmid-19467157-2024-05-16-f0c75ce95f3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-19467157-thymosin-alpha-1-v1 SHA-256: 29d72004eab4ecc560429f230ea308e72f5f1c2e9f229a645cc6e88f54703511.

---

<a id="pubmed-pmid-20194853-thymosin-alpha-1-v1"></a>

## Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.

> PubMed lists PMID 20194853 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20194853-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20194853-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20194853-thymosin-alpha-1-v1
- Content SHA-256: `ec89e4416ec91454ce54601445256701a3466612718326c2e2d8d91e9df9ceb7`

### Claims and source pins

#### Headline

Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. ([`pubmed-observation-pmid-20194853-2025-04-28-f8276733103c`](#source-pubmed-observation-pmid-20194853-2025-04-28-f8276733103c))

#### Summary

PubMed lists PMID 20194853 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20194853-2025-04-28-f8276733103c`](#source-pubmed-observation-pmid-20194853-2025-04-28-f8276733103c))

#### Paragraph 1

PubMed lists PMID 20194853 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20194853-2025-04-28-f8276733103c`](#source-pubmed-observation-pmid-20194853-2025-04-28-f8276733103c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20194853-2025-04-28-f8276733103c`](#source-pubmed-observation-pmid-20194853-2025-04-28-f8276733103c))

### Sources

<a id="source-pubmed-observation-pmid-20194853-2025-04-28-f8276733103c"></a>
- **Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. · retained source version 1:2025-04-28:current:f8276733103c11208a9ad634a14192fab92805dc2adca3d1f5de1b38fdd3171c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20194853/) (`pubmed-observation-pmid-20194853-2025-04-28-f8276733103c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20194853-thymosin-alpha-1-v1 SHA-256: ec89e4416ec91454ce54601445256701a3466612718326c2e2d8d91e9df9ceb7.

---

<a id="pubmed-pmid-20536445-thymosin-alpha-1-v1"></a>

## Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1.

> PubMed lists PMID 20536445 in Annals of the New York Academy of Sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20536445-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20536445-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536445-thymosin-alpha-1-v1
- Content SHA-256: `ce4457f3f4766fd1c9e7833f7ca560d1bff67118def1f797b667ec98d001a7b9`

### Claims and source pins

#### Headline

Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. ([`pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee`](#source-pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee))

#### Summary

PubMed lists PMID 20536445 in Annals of the New York Academy of Sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee`](#source-pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee))

#### Paragraph 1

PubMed lists PMID 20536445 in Annals of the New York Academy of Sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee`](#source-pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee`](#source-pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee))

### Sources

<a id="source-pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee"></a>
- **Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. · retained source version 1:2018-12-01:current:fcd077bef0ee56aa3ff03b18a914df8fbe1844505a44eb243c4bf706271734f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20536445/) (`pubmed-observation-pmid-20536445-2018-12-01-fcd077bef0ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536445-thymosin-alpha-1-v1 SHA-256: ce4457f3f4766fd1c9e7833f7ca560d1bff67118def1f797b667ec98d001a7b9.

---

<a id="pubmed-pmid-20536460-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1: past clinical experience and future promise.

> PubMed lists PMID 20536460 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20536460-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20536460-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536460-thymosin-alpha-1-v1
- Content SHA-256: `23a90c8381d64aa595449f48de5eca423f7fe6b2a6a1eebfbc6746b916d092f7`

### Claims and source pins

#### Headline

Thymosin alpha 1: past clinical experience and future promise. ([`pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316`](#source-pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316))

#### Summary

PubMed lists PMID 20536460 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316`](#source-pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316))

#### Paragraph 1

PubMed lists PMID 20536460 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316`](#source-pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316`](#source-pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316))

### Sources

<a id="source-pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316"></a>
- **Thymosin alpha 1: past clinical experience and future promise. · retained source version 1:2026-01-28:current:219ebe73a316eb4e41acbca4fc5a64cb4133a5cc476ee2644fcab8664a089348** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20536460/) (`pubmed-observation-pmid-20536460-2026-01-28-219ebe73a316`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1: past clinical experience and future promise." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536460-thymosin-alpha-1-v1 SHA-256: 23a90c8381d64aa595449f48de5eca423f7fe6b2a6a1eebfbc6746b916d092f7.

---

<a id="pubmed-pmid-20536461-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.

> PubMed lists PMID 20536461 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20536461-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20536461-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536461-thymosin-alpha-1-v1
- Content SHA-256: `ff58de5c6366a76173e3c0ea03d2b0187cfc7c14ee6b64aa98bfb09a5d252cc7`

### Claims and source pins

#### Headline

Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof. ([`pubmed-observation-pmid-20536461-2018-12-01-ef2debece004`](#source-pubmed-observation-pmid-20536461-2018-12-01-ef2debece004))

#### Summary

PubMed lists PMID 20536461 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536461-2018-12-01-ef2debece004`](#source-pubmed-observation-pmid-20536461-2018-12-01-ef2debece004))

#### Paragraph 1

PubMed lists PMID 20536461 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536461-2018-12-01-ef2debece004`](#source-pubmed-observation-pmid-20536461-2018-12-01-ef2debece004))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20536461-2018-12-01-ef2debece004`](#source-pubmed-observation-pmid-20536461-2018-12-01-ef2debece004))

### Sources

<a id="source-pubmed-observation-pmid-20536461-2018-12-01-ef2debece004"></a>
- **Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof. · retained source version 1:2018-12-01:current:ef2debece00452abe1176a215d8bac0538153ba20e43ed14123b15de6ad1ddab** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20536461/) (`pubmed-observation-pmid-20536461-2018-12-01-ef2debece004`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536461-thymosin-alpha-1-v1 SHA-256: ff58de5c6366a76173e3c0ea03d2b0187cfc7c14ee6b64aa98bfb09a5d252cc7.

---

<a id="pubmed-pmid-20536462-thymosin-alpha-1-v1"></a>

## Thymalfasin in the treatment of hepatitis B and C.

> PubMed lists PMID 20536462 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20536462-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20536462-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536462-thymosin-alpha-1-v1
- Content SHA-256: `8b9a3e05e272caf7cbf2938a320a043bbb3d13cc1c62c2f5ba389ef20854d900`

### Claims and source pins

#### Headline

Thymalfasin in the treatment of hepatitis B and C. ([`pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60`](#source-pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60))

#### Summary

PubMed lists PMID 20536462 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60`](#source-pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60))

#### Paragraph 1

PubMed lists PMID 20536462 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60`](#source-pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60`](#source-pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60))

### Sources

<a id="source-pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60"></a>
- **Thymalfasin in the treatment of hepatitis B and C. · retained source version 1:2026-01-28:current:9c7e9805ba601906e0e796df14675ba76015a25b36580c30c2847d6f1085ca52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20536462/) (`pubmed-observation-pmid-20536462-2026-01-28-9c7e9805ba60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymalfasin in the treatment of hepatitis B and C." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-20536462-thymosin-alpha-1-v1 SHA-256: 8b9a3e05e272caf7cbf2938a320a043bbb3d13cc1c62c2f5ba389ef20854d900.

---

<a id="pubmed-pmid-21272455-thymosin-alpha-1-v1"></a>

## \[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis\].

> PubMed lists PMID 21272455 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Meta-Analysis, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21272455-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21272455-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-21272455-thymosin-alpha-1-v1
- Content SHA-256: `32d41965cf74a4431aac9df53c06f67d59887e52663ae744ba2b63aefdf16c2c`

### Claims and source pins

#### Headline

\[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis\]. ([`pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488`](#source-pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488))

#### Summary

PubMed lists PMID 21272455 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Meta-Analysis, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488`](#source-pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488))

#### Paragraph 1

PubMed lists PMID 21272455 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Meta-Analysis, with publication-date metadata of 2011-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488`](#source-pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488`](#source-pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488))

### Sources

<a id="source-pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488"></a>
- **\[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis\]. · retained source version 1:2018-12-01:current:830b7ea73488759109790a60027858a4f967e371ebb365ee07b071325b4bf919** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21272455/) (`pubmed-observation-pmid-21272455-2018-12-01-830b7ea73488`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-21272455-thymosin-alpha-1-v1 SHA-256: 32d41965cf74a4431aac9df53c06f67d59887e52663ae744ba2b63aefdf16c2c.

---

<a id="pubmed-pmid-22010537-thymosin-alpha-1-v1"></a>

## Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review.

> PubMed lists PMID 22010537 in Journal of preventive medicine and hygiene as Journal Article, Review, with publication-date metadata of 2011-09 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22010537-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22010537-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-22010537-thymosin-alpha-1-v1
- Content SHA-256: `f86dd190e2b26b04136b2872b612603401cdd7be771d6d46612bcf9283f4d9a1`

### Claims and source pins

#### Headline

Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. ([`pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24`](#source-pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24))

#### Summary

PubMed lists PMID 22010537 in Journal of preventive medicine and hygiene as Journal Article, Review, with publication-date metadata of 2011-09 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24`](#source-pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24))

#### Paragraph 1

PubMed lists PMID 22010537 in Journal of preventive medicine and hygiene as Journal Article, Review, with publication-date metadata of 2011-09 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24`](#source-pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24`](#source-pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24))

### Sources

<a id="source-pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24"></a>
- **Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. · retained source version 1:2018-12-01:current:b34bb820cf24599181ea17e2eed3e60171e2afc0e9975bb6999f46239441a773** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22010537/) (`pubmed-observation-pmid-22010537-2018-12-01-b34bb820cf24`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-22010537-thymosin-alpha-1-v1 SHA-256: f86dd190e2b26b04136b2872b612603401cdd7be771d6d46612bcf9283f4d9a1.

---

<a id="pubmed-pmid-22233415-thymosin-alpha-1-v1"></a>

## Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?

> PubMed lists PMID 22233415 in Journal of viral hepatitis as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22233415-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22233415-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-22233415-thymosin-alpha-1-v1
- Content SHA-256: `2effd1b924983893d749e72a2a91834316560856c4d69ab3765ba09853369caf`

### Claims and source pins

#### Headline

Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? ([`pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2`](#source-pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2))

#### Summary

PubMed lists PMID 22233415 in Journal of viral hepatitis as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2`](#source-pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2))

#### Paragraph 1

PubMed lists PMID 22233415 in Journal of viral hepatitis as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-01 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2`](#source-pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2`](#source-pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2))

### Sources

<a id="source-pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2"></a>
- **Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? · retained source version 1:2018-12-01:current:b8e16df877b207e58840cfc81cb893820fe12e45e32226958cf53a1ac854ec6a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22233415/) (`pubmed-observation-pmid-22233415-2018-12-01-b8e16df877b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-22233415-thymosin-alpha-1-v1 SHA-256: 2effd1b924983893d749e72a2a91834316560856c4d69ab3765ba09853369caf.

---

<a id="pubmed-pmid-28106477-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1 and HIV-1: recent advances and future perspectives.

> PubMed lists PMID 28106477 in Future microbiology as Journal Article, Review, with publication-date metadata of 2017-01-20 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28106477-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28106477-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-28106477-thymosin-alpha-1-v1
- Content SHA-256: `a50875b8b3545e740d78bf71dec64a605f825de292592c2ae73f5ae207f61587`

### Claims and source pins

#### Headline

Thymosin alpha 1 and HIV-1: recent advances and future perspectives. ([`pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7`](#source-pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7))

#### Summary

PubMed lists PMID 28106477 in Future microbiology as Journal Article, Review, with publication-date metadata of 2017-01-20 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7`](#source-pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7))

#### Paragraph 1

PubMed lists PMID 28106477 in Future microbiology as Journal Article, Review, with publication-date metadata of 2017-01-20 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7`](#source-pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7`](#source-pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7))

### Sources

<a id="source-pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7"></a>
- **Thymosin alpha 1 and HIV-1: recent advances and future perspectives. · retained source version 1:2018-12-02:current:3fa552d98ba79ef3a09936d5d3224b42e29c37ef513b8496b672c71219036e96** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28106477/) (`pubmed-observation-pmid-28106477-2018-12-02-3fa552d98ba7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1 and HIV-1: recent advances and future perspectives." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-28106477-thymosin-alpha-1-v1 SHA-256: a50875b8b3545e740d78bf71dec64a605f825de292592c2ae73f5ae207f61587.

---

<a id="pubmed-pmid-30063860-thymosin-alpha-1-v1"></a>

## Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.

> PubMed lists PMID 30063860 in Expert opinion on biological therapy as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30063860-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-01-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30063860-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063860-thymosin-alpha-1-v1
- Content SHA-256: `5181762db5f38490b95fb022f7bb499754050174370b1c086990f1a5a8ac9bb5`

### Claims and source pins

#### Headline

Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. ([`pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347`](#source-pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347))

#### Summary

PubMed lists PMID 30063860 in Expert opinion on biological therapy as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347`](#source-pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347))

#### Paragraph 1

PubMed lists PMID 30063860 in Expert opinion on biological therapy as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347`](#source-pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347`](#source-pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347))

### Sources

<a id="source-pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347"></a>
- **Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. · retained source version 1:2019-01-11:current:f8dc3b0f53473654ac4b4e0f3400f5017a81f345a42a720d5f5bb91e71a9847e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30063860/) (`pubmed-observation-pmid-30063860-2019-01-11-f8dc3b0f5347`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063860-thymosin-alpha-1-v1 SHA-256: 5181762db5f38490b95fb022f7bb499754050174370b1c086990f1a5a8ac9bb5.

---

<a id="pubmed-pmid-30063864-thymosin-alpha-1-v1"></a>

## Serum thymosin alpha 1 levels in normal and pathological conditions.

> PubMed lists PMID 30063864 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30063864-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30063864-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063864-thymosin-alpha-1-v1
- Content SHA-256: `ba48fd951ea1e7fc1e6a169615fe5fcdfb089908bb89a8d97fbadd091197a24c`

### Claims and source pins

#### Headline

Serum thymosin alpha 1 levels in normal and pathological conditions. ([`pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706`](#source-pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706))

#### Summary

PubMed lists PMID 30063864 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706`](#source-pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706))

#### Paragraph 1

PubMed lists PMID 30063864 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706`](#source-pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706`](#source-pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706))

### Sources

<a id="source-pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706"></a>
- **Serum thymosin alpha 1 levels in normal and pathological conditions. · retained source version 1:2019-06-25:current:e86d24d6c7066692e2de233a75fb5d7d2b8b311724592a2a154a889f0dffbd00** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30063864/) (`pubmed-observation-pmid-30063864-2019-06-25-e86d24d6c706`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Serum thymosin alpha 1 levels in normal and pathological conditions." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063864-thymosin-alpha-1-v1 SHA-256: ba48fd951ea1e7fc1e6a169615fe5fcdfb089908bb89a8d97fbadd091197a24c.

---

<a id="pubmed-pmid-30063866-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1 treatment for patients with sepsis.

> PubMed lists PMID 30063866 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30063866-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30063866-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063866-thymosin-alpha-1-v1
- Content SHA-256: `512abd2779360063a3f0a74a9b81ad51064266a37e6fc7ceb9de3a4a6fb00391`

### Claims and source pins

#### Headline

Thymosin alpha 1 treatment for patients with sepsis. ([`pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb`](#source-pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb))

#### Summary

PubMed lists PMID 30063866 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb`](#source-pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb))

#### Paragraph 1

PubMed lists PMID 30063866 in Expert opinion on biological therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb`](#source-pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb`](#source-pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb))

### Sources

<a id="source-pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb"></a>
- **Thymosin alpha 1 treatment for patients with sepsis. · retained source version 1:2019-06-25:current:4a89748ecabb725ac303127ec4e8099ef7ec603f248f09a7158c7de5af54a272** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30063866/) (`pubmed-observation-pmid-30063866-2019-06-25-4a89748ecabb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1 treatment for patients with sepsis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-30063866-thymosin-alpha-1-v1 SHA-256: 512abd2779360063a3f0a74a9b81ad51064266a37e6fc7ceb9de3a4a6fb00391.

---

<a id="pubmed-pmid-33362999-thymosin-alpha-1-v1"></a>

## Thymosin alpha 1: A comprehensive review of the literature.

> PubMed lists PMID 33362999 in World journal of virology as Journal Article, Review, with publication-date metadata of 2020-12-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33362999-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-12-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33362999-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-33362999-thymosin-alpha-1-v1
- Content SHA-256: `c69d50c8110ecd9822c06a0e4ebbdd082ed5d2af2a17eaa8ad9c4080736d3bda`

### Claims and source pins

#### Headline

Thymosin alpha 1: A comprehensive review of the literature. ([`pubmed-observation-pmid-33362999-2020-12-29-96f371610863`](#source-pubmed-observation-pmid-33362999-2020-12-29-96f371610863))

#### Summary

PubMed lists PMID 33362999 in World journal of virology as Journal Article, Review, with publication-date metadata of 2020-12-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33362999-2020-12-29-96f371610863`](#source-pubmed-observation-pmid-33362999-2020-12-29-96f371610863))

#### Paragraph 1

PubMed lists PMID 33362999 in World journal of virology as Journal Article, Review, with publication-date metadata of 2020-12-15 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33362999-2020-12-29-96f371610863`](#source-pubmed-observation-pmid-33362999-2020-12-29-96f371610863))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33362999-2020-12-29-96f371610863`](#source-pubmed-observation-pmid-33362999-2020-12-29-96f371610863))

### Sources

<a id="source-pubmed-observation-pmid-33362999-2020-12-29-96f371610863"></a>
- **Thymosin alpha 1: A comprehensive review of the literature. · retained source version 1:2020-12-29:current:96f371610863b6832c5115cbae5800623e3cf9342dceaaf04af184bc9285d9ef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33362999/) (`pubmed-observation-pmid-33362999-2020-12-29-96f371610863`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin alpha 1: A comprehensive review of the literature." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-33362999-thymosin-alpha-1-v1 SHA-256: c69d50c8110ecd9822c06a0e4ebbdd082ed5d2af2a17eaa8ad9c4080736d3bda.

---

<a id="pubmed-pmid-38903817-thymosin-alpha-1-v1"></a>

## Phenotypic drug discovery: a case for thymosin alpha-1.

> PubMed lists PMID 38903817 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2024-06-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38903817-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-06-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38903817-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-38903817-thymosin-alpha-1-v1
- Content SHA-256: `971cf04737d068ad6ff282284bc31fba4532dad0a6b30556ef7ac1a9bd40b223`

### Claims and source pins

#### Headline

Phenotypic drug discovery: a case for thymosin alpha-1. ([`pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd`](#source-pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd))

#### Summary

PubMed lists PMID 38903817 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2024-06-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd`](#source-pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd))

#### Paragraph 1

PubMed lists PMID 38903817 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2024-06-06 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd`](#source-pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd`](#source-pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd))

### Sources

<a id="source-pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd"></a>
- **Phenotypic drug discovery: a case for thymosin alpha-1. · retained source version 1:2024-06-22:current:1868701eb2fd1a0c736c5b24e4c20c1b9a6929abbba785eb518a23d7ef017fb7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38903817/) (`pubmed-observation-pmid-38903817-2024-06-22-1868701eb2fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phenotypic drug discovery: a case for thymosin alpha-1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-38903817-thymosin-alpha-1-v1 SHA-256: 971cf04737d068ad6ff282284bc31fba4532dad0a6b30556ef7ac1a9bd40b223.

---

<a id="pubmed-pmid-39648386-thymosin-alpha-1-v1"></a>

## Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 39648386 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2024-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39648386-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39648386-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-39648386-thymosin-alpha-1-v1
- Content SHA-256: `bcba6c5a557bb416f1cdfcda869de6ae8ec3780a9af0d1ebaac8929a54efe99b`

### Claims and source pins

#### Headline

Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08`](#source-pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08))

#### Summary

PubMed lists PMID 39648386 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2024-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08`](#source-pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08))

#### Paragraph 1

PubMed lists PMID 39648386 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2024-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08`](#source-pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08`](#source-pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08))

### Sources

<a id="source-pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08"></a>
- **Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. · retained source version 1:2024-12-16:current:7ec48cc3db08aab3eb72022a99167f50301ea021259fe1ef0d1c93a6dc778825** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39648386/) (`pubmed-observation-pmid-39648386-2024-12-16-7ec48cc3db08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-39648386-thymosin-alpha-1-v1 SHA-256: bcba6c5a557bb416f1cdfcda869de6ae8ec3780a9af0d1ebaac8929a54efe99b.

---

<a id="pubmed-pmid-41373628-thymosin-alpha-1-v1"></a>

## Aging and Thymosin Alpha-1.

> PubMed lists PMID 41373628 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-11-27 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41373628-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41373628-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-41373628-thymosin-alpha-1-v1
- Content SHA-256: `6517c4d45db77169760b526ae693f5950d368c2777d8fa8168dcf390a6dfa836`

### Claims and source pins

#### Headline

Aging and Thymosin Alpha-1. ([`pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5`](#source-pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5))

#### Summary

PubMed lists PMID 41373628 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-11-27 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5`](#source-pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5))

#### Paragraph 1

PubMed lists PMID 41373628 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-11-27 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5`](#source-pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5`](#source-pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5))

### Sources

<a id="source-pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5"></a>
- **Aging and Thymosin Alpha-1. · retained source version 1:2025-12-14:current:4306cfc99eb51a5989e82d127a8ba6a3047b5c75426373f7713a1c47411a6cac** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41373628/) (`pubmed-observation-pmid-41373628-2025-12-14-4306cfc99eb5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Aging and Thymosin Alpha-1." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-41373628-thymosin-alpha-1-v1 SHA-256: 6517c4d45db77169760b526ae693f5950d368c2777d8fa8168dcf390a6dfa836.

---

<a id="pubmed-pmid-41749205-thymosin-alpha-1-v1"></a>

## Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.

> PubMed lists PMID 41749205 in BMC medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41749205-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41749205-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-41749205-thymosin-alpha-1-v1
- Content SHA-256: `ffae1b2e185e36a365192045015afa0eb45a6d294f7eb267ed92cf7fa0a1c857`

### Claims and source pins

#### Headline

Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. ([`pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5`](#source-pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5))

#### Summary

PubMed lists PMID 41749205 in BMC medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5`](#source-pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5))

#### Paragraph 1

PubMed lists PMID 41749205 in BMC medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5`](#source-pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5`](#source-pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5))

### Sources

<a id="source-pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5"></a>
- **Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. · retained source version 1:2026-09-14:current:69d068216aa50f316e5953d91bcee4c29ce394f8061dde437de0357d548d4d3e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41749205/) (`pubmed-observation-pmid-41749205-2026-09-14-69d068216aa5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-41749205-thymosin-alpha-1-v1 SHA-256: ffae1b2e185e36a365192045015afa0eb45a6d294f7eb267ed92cf7fa0a1c857.

---

<a id="pubmed-pmid-42797537-thymosin-alpha-1-v1"></a>

## Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.

> PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42797537-thymosin-alpha-1:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42797537-thymosin-alpha-1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-42797537-thymosin-alpha-1-v1
- Content SHA-256: `dd9ff7f53f8b5ca2b57684275d4d79980ba8935dd5ad9e664cae16dbc1d25d01`

### Claims and source pins

#### Headline

Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. ([`pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01`](#source-pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01))

#### Summary

PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01`](#source-pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01))

#### Paragraph 1

PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01`](#source-pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01`](#source-pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01))

### Sources

<a id="source-pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01"></a>
- **Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. · retained source version 1:2026-09-29:current:f5d603c32e01271e609945a4d8e4cd8b3521239cb60764f0fb7e0ce900183af5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42797537/) (`pubmed-observation-pmid-42797537-2026-09-29-f5d603c32e01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/thymosin-alpha-1.json#pubmed-pmid-42797537-thymosin-alpha-1-v1 SHA-256: dd9ff7f53f8b5ca2b57684275d4d79980ba8935dd5ad9e664cae16dbc1d25d01.

